WO1990014103A1 - Conjugue polypeptide-anticorps empechant l'adhesion des cellules - Google Patents

Conjugue polypeptide-anticorps empechant l'adhesion des cellules Download PDF

Info

Publication number
WO1990014103A1
WO1990014103A1 PCT/US1990/002746 US9002746W WO9014103A1 WO 1990014103 A1 WO1990014103 A1 WO 1990014103A1 US 9002746 W US9002746 W US 9002746W WO 9014103 A1 WO9014103 A1 WO 9014103A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
polypeptide
rgd
molecule
cell
Prior art date
Application number
PCT/US1990/002746
Other languages
English (en)
Inventor
David A. Cheresh
Original Assignee
Scripps Clinic And Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Clinic And Research Foundation filed Critical Scripps Clinic And Research Foundation
Publication of WO1990014103A1 publication Critical patent/WO1990014103A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Le conjugué polypeptide-anticorps contient un polypeptide de liaison d'intégrine attaché à une molécule d'un anticorps qui a une immunoréaction avec des antigènes de surfaces de cellules d'adhésion. Des compositions thérapeutiques et des procédés utilisant ces compositions sont également décrits et utilisent le conjugué polypeptide-anticorps de l'invention pour inhiber l'adhésion des cellules et des processus dépendants de l'adhésion des cellules telles que la croissance de tumeurs et l'agrégation de plaquettes.
PCT/US1990/002746 1989-05-17 1990-05-15 Conjugue polypeptide-anticorps empechant l'adhesion des cellules WO1990014103A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36261789A 1989-05-17 1989-05-17
US362,617 1989-05-17

Publications (1)

Publication Number Publication Date
WO1990014103A1 true WO1990014103A1 (fr) 1990-11-29

Family

ID=23426812

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/002746 WO1990014103A1 (fr) 1989-05-17 1990-05-15 Conjugue polypeptide-anticorps empechant l'adhesion des cellules

Country Status (6)

Country Link
AU (1) AU5815990A (fr)
CA (1) CA2016962A1 (fr)
GR (1) GR900100372A (fr)
IE (1) IE901736L (fr)
PT (1) PT94067A (fr)
WO (1) WO1990014103A1 (fr)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991008298A2 (fr) * 1989-11-22 1991-06-13 Genentech, Inc. Proteines de fusion comprenant une proteine de fixation de ligand et une proteine plasmatique stable
EP0466505A2 (fr) * 1990-07-13 1992-01-15 Fujita Health University Anticorps artificiel
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
WO1995025543A1 (fr) * 1994-03-18 1995-09-28 The Scripps Research Institute Compositions inhibitrices de l'angiogenese et procedes correspondants
US5612311A (en) * 1990-04-06 1997-03-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5780303A (en) * 1990-04-06 1998-07-14 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
WO1999024462A2 (fr) * 1997-11-07 1999-05-20 Conjuchem, Inc. Nouveaux conjugues de peptides renfermant rgd et supports endogenes
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
EP1223962A1 (fr) * 1999-09-23 2002-07-24 The Scripps Research Institute Procede et compositions pour inhiber la formation d'adherences
US6521594B1 (en) 1990-04-06 2003-02-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US6586002B2 (en) 1993-03-23 2003-07-01 Alza Corporation Enhanced circulation effector composition and method
US7521419B2 (en) 2001-07-10 2009-04-21 Ge Healthcare As Peptide-based compounds
US7737252B2 (en) 2000-09-26 2010-06-15 Ge Healthcare As Peptide-based compounds
WO2010075058A1 (fr) 2008-12-23 2010-07-01 Ge Healthcare Limited Application d'un composé basé sur le peptide 99mtc à l'imagerie de la moelle osseuse
WO2011112549A3 (fr) * 2010-03-10 2012-01-19 Emory University Compositions conjuguées sensibles à la température, et applications correspondantes
US8404802B2 (en) 2000-04-12 2013-03-26 Ge Healthcare As Peptide-based compounds

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06507641A (ja) * 1991-05-03 1994-09-01 ザ ロックフェラー ユニバーシティ 白血球ｃｒ３に対する内皮細胞リガンド認識抗体
WO1994009034A1 (fr) * 1992-10-12 1994-04-28 Agen Limited Anticoagulant ciblant les caillots, ses procedes de fabrication et d'utilisation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4675382A (en) * 1982-05-12 1987-06-23 President And Fellows Of Harvard College Hybrid protein

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1203164A (fr) * 1982-03-09 1986-04-15 Thomas J. Mckearn Conjugats d'anticorps

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4675382A (en) * 1982-05-12 1987-06-23 President And Fellows Of Harvard College Hybrid protein

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BLOOD, Volume 71, No. 4, issued April 1988, D.R. PHILLIPS et al.: "The Platelet Membrane Glycoprotein IIb-IIIa complex". See page 831-833. *
EXPERIMENTAL CELL RESEARCH, Volume 182, issued 1989, Y.N. DANILOU et al.: "(Arg-Gly-Asp) n-Albumin Conjugates as a Model Substratum for Integrin-Mediated Cell Adhesion". See abstract on page 186 and 187-188. *
THE JOURNAL OF CELL BIOLOGY, Volume 104, issued March 1987, I.I. SINGER et al.: "The Fibronectin Cell Attachment Sequence Arg-Gly-Asp-Ser promotes Focal Contact Formation during Early Fibroblast Attachment and Spreading". See page 575. *
THE JOURNAL OF CELL BIOLOGY, Volume 106, issued March 1988, K.R. GEHLSEN et al.: "Inhibition of In Vitro Tumor Cell Invasion by Arg-Gly-Asp-containing Synthetic Peptides". See pages 925, 928 and 929. *

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5455165A (en) * 1989-02-23 1995-10-03 Genentech, Inc. Expression vector encoding hybrid immunoglobulins
US5514582A (en) * 1989-02-23 1996-05-07 Genentech, Inc. Recombinant DNA encoding hybrid immunoglobulins
US5714147A (en) * 1989-02-23 1998-02-03 Genentech Inc. Hybrid immunoglobulins
WO1991008298A3 (fr) * 1989-11-22 1991-10-17 Genentech Inc Proteines de fusion comprenant une proteine de fixation de ligand et une proteine plasmatique stable
WO1991008298A2 (fr) * 1989-11-22 1991-06-13 Genentech, Inc. Proteines de fusion comprenant une proteine de fixation de ligand et une proteine plasmatique stable
US5780303A (en) * 1990-04-06 1998-07-14 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US6521594B1 (en) 1990-04-06 2003-02-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US6395873B1 (en) 1990-04-06 2002-05-28 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5612311A (en) * 1990-04-06 1997-03-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5475100A (en) * 1990-07-13 1995-12-12 Fujita Health University Artificial antibody
EP0466505A3 (en) * 1990-07-13 1992-08-19 Fujita Health University Artificial antibody
EP0466505A2 (fr) * 1990-07-13 1992-01-15 Fujita Health University Anticorps artificiel
US7160554B2 (en) 1993-03-23 2007-01-09 Alza Corporation Enhanced circulation effector composition and method
US6586002B2 (en) 1993-03-23 2003-07-01 Alza Corporation Enhanced circulation effector composition and method
US7150882B2 (en) 1993-03-23 2006-12-19 Alza Corporation Enhanced circulation effector composition and method
WO1995025543A1 (fr) * 1994-03-18 1995-09-28 The Scripps Research Institute Compositions inhibitrices de l'angiogenese et procedes correspondants
WO1999024462A3 (fr) * 1997-11-07 1999-08-26 Conjuchem Inc Nouveaux conjugues de peptides renfermant rgd et supports endogenes
WO1999024462A2 (fr) * 1997-11-07 1999-05-20 Conjuchem, Inc. Nouveaux conjugues de peptides renfermant rgd et supports endogenes
EP1223962A1 (fr) * 1999-09-23 2002-07-24 The Scripps Research Institute Procede et compositions pour inhiber la formation d'adherences
EP1223962A4 (fr) * 1999-09-23 2004-01-21 Scripps Research Inst Procede et compositions pour inhiber la formation d'adherences
AU781442B2 (en) * 1999-09-23 2005-05-26 Scripps Research Institute, The Method and compositions for inhibiting adhesion formation
US8404802B2 (en) 2000-04-12 2013-03-26 Ge Healthcare As Peptide-based compounds
US8258101B2 (en) 2000-09-26 2012-09-04 Ge Healthcare As Peptide-based compounds
US7737252B2 (en) 2000-09-26 2010-06-15 Ge Healthcare As Peptide-based compounds
US7521419B2 (en) 2001-07-10 2009-04-21 Ge Healthcare As Peptide-based compounds
US7994134B2 (en) 2001-07-10 2011-08-09 Ge Healthcare As Peptide-based compounds
EP2347771A1 (fr) 2001-07-10 2011-07-27 Ge Healthcare As Composés peptidiques pour imagerie ciblée.
US8299030B2 (en) 2001-07-10 2012-10-30 Ge Healthcare Limited Peptide-based compounds
WO2010075058A1 (fr) 2008-12-23 2010-07-01 Ge Healthcare Limited Application d'un composé basé sur le peptide 99mtc à l'imagerie de la moelle osseuse
WO2011112549A3 (fr) * 2010-03-10 2012-01-19 Emory University Compositions conjuguées sensibles à la température, et applications correspondantes
US9035028B2 (en) 2010-03-10 2015-05-19 Emory University Temperature sensitive conjugate compositions

Also Published As

Publication number Publication date
GR900100372A (el) 1991-10-10
PT94067A (pt) 1991-02-08
IE901736L (en) 1990-11-17
AU5815990A (en) 1990-12-18
CA2016962A1 (fr) 1990-11-17

Similar Documents

Publication Publication Date Title
FI100184B (fi) Ihmisen kudostekijään liittyvä DNA-kappale ja yhdistelmä-DNA-molekyyli sekä menetelmä proteiinin valmistamiseksi
WO1990014103A1 (fr) Conjugue polypeptide-anticorps empechant l'adhesion des cellules
US7696324B2 (en) Humanized antibodies
US5470738A (en) Antibodies that bind to a ligand-induced binding site on GPIIIa
US5149780A (en) Peptides and antibodies that inhibit integrin-ligand binding
US5204445A (en) Peptides and antibodies that inhibit integrin-ligand binding
US5437864A (en) Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor
ES2283114T3 (es) Anticuerpo con capacidad de produccion mejorada.
EP0619839B1 (fr) Nouveaux polypeptides promoteurs de la fixation de cellules
US6001978A (en) Human tissue factor related DNA segments polypeptides and antibodies
JPH05507197A (ja) 結合部位を含む可溶性ペプチド類縁体
JPH05502228A (ja) インテグリン―リガンド結合を阻害するペプチドおよび抗体
JP3455743B2 (ja) ヒトｐｄｇｆベータ・レセプタに対する阻害性免疫グロブリン・ポリペプチド
EP0368486A3 (fr) Inhibiteurs de l'attachement des plaquettes
CA2348026C (fr) Anticorps anti-semp1, methodes de production et utilisations connexes
WO2022057871A1 (fr) Anticorps bispécifique anti-4-1bb-anti-pd-l1, composition pharmaceutique et utilisation associées
WO1989005155A1 (fr) Anticorps monoclonal utilise contre le recepteur d'adhesion a direction rgd de cellules endotheliales
US6482410B1 (en) Cytotactin derivatives that stimulate attachment and neurite outgrowth, and methods of making same
ES2316574T3 (es) Anticuerpo de tipo humano contra el factor viii de la coagulacion sanguinea.
WO2019192493A1 (fr) Anticorps monoclonal anti-lag-3 humain et son utilisation
CA3189730A1 (fr) Anticorps anti-tigit et ses methodes d'utilisation
CN114340671A (zh) 对gpc3特异性的抗体及其使用方法
WO1994014848A1 (fr) Immunoglobulines produites par genie genetique
IE20040562A1 (en) Human tissue factor related DNA segments, polypeptides and antibodies.
IE83847B1 (en) Human tissue factor related DNA segments, polypeptides and antibodies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE